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Abstract
Objective: To analyze prevalence and risk factors for retinopathy of prematurity (ROP) among preterm infants
born small for gestational age (SGA) and appropriate for gestational age (AGA).
Methods:Aprospectivecohort study includedpreterm infantswithbirthweight (BW)≤1,500gramsandgestational
age (GA) ≤ 32 weeks, divided into two groups: AGA or SGA. Prevalences and risk factors for ROP were determined in
both groups. Logistic regression was used for the significant variables after univariate analysis.
Results: A total of 345 patients were examined: 199 included in the AGA group and 146 in the SGA. Mean BW and
GA in the whole cohort (345 patients) were 1,128.12 grams (±239.9) and 29.7 weeks (±1.9), respectively. The
prevalenceof any stageROPandsevereROP (needing treatment)was29.6and7.0%, respectively.ROP inanyevolutive
stage developed in 66 AGA (33.2%) and in 36 SGA (24.7%) (p= 0.111). Severe ROP occurred in 15 AGA (7.5%) and in
nineSGA (6.2%) (p=0.779). After adjusted logistic regression,weight gain frombirth to sixthweek of life and need for
blood transfusions were found to be significant risk factors for ROP in both groups.
Conclusions: This study has shown that being SGAwas not a significant risk factor for any stage ROP or for severe
ROP in this cohort and, also, that the risk factors for ROP were similar among SGA and AGA very-low-birth-weight
preterm babies.
J Pediatr (Rio J). 2009;85(1):48-54: Prematurity, retinopathy of prematurity, very low birth weight infant, risk factors,
small for gestational age, appropriate for gestational age.
Introduction
Retinopathy of prematurity (ROP) is in continuous study
throughout the world due to the rise in survival rates among
very lowbirthweight (VLBW)preterm infants, i.e., those born
withweight≤1,500grams. This,which stems from thehigher
quality of perinatal care, has led to a significant increase in
the presence of comorbidities related to preterm birth, some
of which have important social consequences, such as blind-
ness secondary to ROP.1,2
ROP is a vasoproliferative retinal disorder which affects
preterm newborns. It can lead to blindness in its natural
course, or when treatment is not provided in time. In Brazil, it
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is estimated that around 1,500 VLBW preterm infants are at
risk of developing severe ROP, and that it may cause up to
500 new cases of blindness every year.3
ROP most often affects lower gestational age (GA) pre-
term infants, even those with few comorbidities, but it can
also be found in larger, though sicker, babies.4-6
Currently, controversy still surrounds the significance of
being small for GA (SGA) for the onset of ROP. This finding,
which has been recently reported,6-9 had already been pub-
licized by the studies of Johnson et al. in 1976,10 and Diste-
fano et al. in 1993,11 which described an association between
infants born SGA and ROP.
ROP does not arise immediately after birth, but rather
around the 34th or 35th week of postconceptional age (PCA).
During that period, the disease can be identified by ophthal-
mologists through fundus examinations; if treated around the
37th or 39th week of PCA, there is still time to avoid severe
and irreversible damage to vision. There is also controversy
surrounding the issue of whether preterm SGA infants would
developROPbefore expected,12,13whichwouldmean that the
optimal time for early ophthalmologic examinations, while
screening ROP among SGA patients, should be earlier than
recommended by the guidelines established in many indus-
trialized countries and which have excellent results in
neonatology.
Trying to answer existing issues in scientific knowledge
about the subject of being SGA and the onset of ROP, starting
on 2002, we designed a prospective study with the goals of
analyzing the prevalence of any stage ROP and severe ROP
which requires treatment, and potential risk factors for the
onset of ROP among preterm infants born appropriate for GA
(AGA) and preterm SGA infants, as well as determining the
moment of onset of severe ROP which requires treatment
among AGA and SGA patients.
Methods
This was a prospective, descriptive cohort study which
included preterm infants with birth weight (BW) ≤ 1,500
grams and GA ≤ 32 weeks at birth admitted to the Neonatal
Intensive Care Unit (NICU) of Hospital de Clínicas de Porto
Alegre (HCPA) betweenOctober 2002andAugust 2008which
survived initial ophthalmologic examination, performed
between the fourth and sixthweek of life, until the 42ndweek
of PCA, at which point temporal peripheral vascularization of
the retina would be complete. This point was chosen as
cross-sectional threshold for ROP prevalence. There were no
exclusion criteria.
Patients were divided into two groups: Group 1 consisted
of all infants bornwithweights AGA. Group 2 (SGA) consisted
of all infants born with weight < 10th percentile over GA,
according to the tables fromAlexander et al.,14which areused
in our institution.
Ophthalmologic examination consisted of binocular indi-
rect ophthalmoscopyunder pupillary dilation, associatedwith
eye drops tropicamide 0.5%, phenylephrine 2.5%, 28 diop-
tries lens (Nikon®, Melville, NY, EUA), and blepharostat
(Alfonso Eye Speculum, Storz®, Bausch & Lomb Inc., San
Dimas, CA, EUA). Scleral depression was used, when neces-
sary, to better identify peripheral retinal alterations. Assess-
ments were repeated periodically, according to Brazilian
guidelines for examining and treatingROP.15 All patientswere
initially examined at the NICU; after discharge, they were
examined at the outpatient department up to the 42nd week
of PCA or until the retinopathy was fully stabilized in the
treatedpatients. All patientswereexaminedby the sameoph-
thalmologists (J.B.F.F., G.U.E., F.B.V.), all professionals quali-
fied for performing the ROP screening. Every patient who
developed ROP was treated by the same ophthalmologist
(J.B.F.F.).
All patientswere treated upon detection of threshold ROP,
defined as the moment fromwhich the risk of an unfavorable
anatomical or functional outcome, or of leading into blind-
ness, is seen in 50% of patients.16
Themoment inwhich patients reachedpre-thresholdROP
was also noted in terms of PCA in weeks. Pre-threshold ROP
was defined following guidelines from the Early Treatment for
Retinopathy of Prematurity Cooperative Group (ET-ROP).17
Primary clinical outcomes were: ROP onset at any evolu-
tionary stage and onset of severe ROP which requires treat-
ment in both groups (AGA/SGA). Disease stages were
recorded according to the 1984/1987 International Classifi-
cation of ROP,18 and correspond to themost severe degree of
retinopathy found in either eye during follow-up. Severe ROP
was defined as disease on stage 3, threshold or higher. ROP
prevalencewas calculated for both patient groups. As second-
ary outcomes, we observed mean GA upon treatment and
pre-threshold disease onset.
The following variables were determined to analyze risk
factors for ROP: BW, GA (assessed by clinical history, early
obstetric echography, and confirmed by clinical examina-
tion), weight gain after birth to sixth week of life (defined as
weight at sixth week of life minus BW), sex, twin pregnancy
(born of single or multiple gestation), use of oxygen in
mechanical ventilation or nasal continuous positive airway
pressure (nasal CPAP), use of indomethacin, surfactant and
erythropoietin, Apgar score at 5th minute, presence of intra-
ventricular hemorrhage (from cranial ultrasound) and need
for blood transfusions. We could not determine the duration
and concentration of oxygen used. This variable, use of oxy-
gen therapy, was considered dichotomous.
Univariate analysiswasperformedon the sameset of vari-
ables for bothgroups.WeusedStudent's t test to analyze con-
tinuous variables for independent samples; for categorical
variables, we used the chi-square test with Yates' correction.
Results were considered significant for p < 0.05.
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Logistic regression was performed after univariate
analysis.
Statistical analyses were performed with the SPSS soft-
ware (SPSS® 14.0 for Windows®, SPSS Inc., Chicago, IL,
EUA). To determine test power, we used application PEPI
(POWR, version 4.0).
The studyprotocol about risk factors forROPwasapproved
by the HCPA Research Ethics Committee under number
03-248 on August 20, 2003.
Results
A total of 450 VLBW (born with weight ≤ 1,500 grams
and/orGA≤32weeks)were examined at theHCPANICUdur-
ing screening sessions for detection of ROP throughout the
periodof the study. The450correspond toapproximately93%
of patients admitted to the institution according to the inclu-
sion criteria of the ROP neonatal screening program, as
defined for Brazil.15
The study included 345 patients with BW ≤ 1,500 grams
andGA≤32weeks. Group 1 (AGA) consisted of 199 patients,
while Group 2 consisted of 146 (SGA). Mean BW among pre-
term infants in the AGA group was 1,155.30±230.2 grams,
while for SGAgroup itwas1,091.10±248.6 grams, p=0.014.
MeanGA among AGA patients was 28.8±1.8weeks, while for
SGA patients it was 30.9±1.3weeks, p< 0.001. Meanweight
gain after birth to sixth week of life was 556.10±277.2 grams
for AGA patients and 625.60±219.1 for SGA ones, p = 0,013
Table 1 shows data for onset of any stage ROP and severe
ROP for groups AGA and SGA. There was no significant differ-
ence among groups in terms of ROP occurrence at any stage
or of severe ROP.
Table 2 presents the univariate analysis of the main risk
factors for ROP in both groups. Among those AGA, BW (p <
0.001), GA (p < 0.001), and weight gain until sixth week of
life (p = 0.001) were significantly lower for patients which
developed ROP, while the use of oxygen therapy in mechani-
cal ventilation (p = 0.016), use of indomethacin (p = 0.010)
and need for blood transfusions (p < 0.001) were signifi-
cantly more common among those who developed ROP.
Among those SGA, BW (p = 0.001), GA (p = 0.036), and
weight gain after birth to sixth week of life were significantly
lower for patients who developed ROP (p < 0.001). The need
for blood transfusionswas significantlymore commonamong
patients who developed ROP at any evolutionary stage (p <
0.001).
After logistic regression adjustments, weight gain after
birth to sixth week of life (odds ratio or OR = 0.997; 95%CI
0.996-0.999; p<0.001) and need for blood transfusions (OR
= 2.958; 95%CI 1.575-5.558; p = 0.001) were considered
significant for onset of ROP among the cohort (Table 3).
Mean GA at which pre-threshold ROP was detected was
35.9±2.7 weeks among AGA patients and 38.3±1.6 weeks
among SGA one, p = 0.61. Mean PCA upon treatment was
37.4±2.7 weeks for AGA patients and 39.9±1.2 weeks for
SGA, p = 0,052. Pre-threshold ROP and threshold ROP diag-
noses occurred, on average, after 9.1±2.1 weeks of life for
AGA patients and after 8.3±1.5 weeks of life for SGA ones, p
= 0.356 and p = 0.140, respectively.
Test power for determining the 8.5 percentage point dif-
ferential inROPprevalencebetweenGroupsAGAandSGAwas
estimated at 40%.
Discussion
Due to the 40% test power of our study, the results allow
us to conclude that being SGA may not be a significant risk
factor for any stage ROP or for severe ROP among VLBW pre-
term patients. The study has also shown that diagnoses of
pre-threshold and threshold ROP (illnesses in more severe
stages andwhich require treatment) were found after the ini-
tial periodic examinations for ROP detection in both patient
groups (AGA and SGA), and that criteria for ROP detection
Table 1 - Prevalence of ROP for the two patient groups, small (SGA) or appropriate for gestational age (AGA)
ROP stages
Group 1, AGA (n = 199)
n (%)
Group 2, SGA (n = 146)
n (%) p
No ROP 133 (66.8) 110 (75.3)
ROP 66 (33.2) 36 (24.7) 0.111
ROP 1 28 (14.1) 15 (10.3)
ROP 2 23 (11.6) 12 (8.2)
ROP 3* 15 (7.5) 7 (4.8)
ROP 4* 0 (0.0) 1 (0.7) 0.779*
ROP 5* 0 (0.0) 1 (0.7)
AGA = appropriate for gestational age; ROP = retinopathy of prematurity; SGA = small for gestational age.
* Severe ROP.
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through ophthalmologic examination between the fourth and
sixth week of life, as recommended for Brazil,15 were able to
detect all caseswhich required treatment in time for its admin-
istration, both for AGA and SGA patients.
The World Health Organization, in its Vision 2020 pro-
gram, has identified ROP as an important cause of blindness
in countrieswith low infantmortality rates.Gilbert et al.19 sug-
gest that ROP is predominant among preterm infants born
with BW < 1,000 grams in industrialized countries, and is on
the rise as an important cause of childhoodblindness in devel-
oping nations such as Brazil, as well as other Latin American
countries, Asia and Eastern Europe, to the higher survival
rates for VLBW preterm infants.
Studies suggest that the incidence and severity of ROP
show an inverted relationship with BWandGA, and few cases
of severe ROP are diagnosed in preterm patients with BW >
1,500 grams orGA>32weeks.20 Severe ROP,which requires
treatment, has greater incidence among patients born at GA
< 28 weeks or with BW< 1,000 grams, though the disease is
still found among babies born at GA 34-35 weeks and BW >
1,500 grams, especially in the presence of several comorbidi-
ties, as reported in India, China, and emerging Eastern Euro-
pean economies.21-24
Our institution is a tertiary referral university hospital,
located at ametropolitan regionwith population of circa 4mil-
lion. ROP prevalence at HCPA has been previously reported
as 24.7% for infants with BW ≤ 1,500 grams and/or GA ≤ 32
weeks between 2002 and 2006.25 In the present study, the
prevalence of severe ROPwas 7.5%among AGA patients and
6.2% among SGA ones.
Recent studies in developed countries suggest that the
first ophthalmologic examination of SGA patients should be
the fourthweekof life, sincemost cases of thresholdROPwere
identified before the 34th week PCA.12,13 Our results diverge
from such statements, however, because we have not found
any statistically significant differences between the onset of
pre-threshold and threshold ROP between AGA and SGA
patients in our cohort of 345 VLBW preterm newborns. Mean
Table 2 - Risk factors significant for ROP in groups 1 (AGA) and 2 (SGA) after univariate analysis
Group 1, AGA (n = 199) Group 2, SGA (n = 146)
Factors
Patients
without ROP
(n = 133)
Patients with
ROP
(n = 66) p
Patients
without ROP
(n = 110)
Patients with
ROP
(n = 36) p
Birth weight (grams)* 1,202.5±199.0 1,060.1±259.3 < 0.001 1,128.7±240.8 976.0±239.6 0.001
Gestational age (weeks)* 29.1±1.6 28.1±1.9 < 0.001 31.0±1.3 30.4±1.5 0.036
Absolute weight gain
(grams)*
602.0±261.9 463.6±286.1 0.001 681.8±198.1 453.7±190.4 < 0.001
Use of oxygen in mechanical
ventilation†
63 (47.4%) 44 (66.7%) 0.016 - - -
Use of indomethacin† 40 (30.1%) 33 (50.0%) 0.010 - - -
Blood transfusions† 73 (54.9%) 54 (81.8%) < 0.001 54 (49.1%) 31 (86.1%) < 0.001
AGA = appropriate for gestational age; ROP = retinopathy of prematurity; SGA = small for gestational age.
* Mean ± standard deviation (Student's t test).
† Chi-square test.
Table 3 - Odds ratio for ROP onset after adjusted logistic regression
Factors OR 95%CI p
Gestational age 0.887 0.749-1.051 0.166
Absolute weight gain 0.997 0.996-0.999 < 0.001
Use of oxygen in mechanical ventilation 1.446 0.831-2.514 0.192
Use of indomethacin 1.276 0.722-2.253 0.402
Need for blood transfusions 2.958 1.575-5.558 0.001
Being SGA 1.024 0.552-1.897 0.941
95%CI = 95% confidence interval; OR = odds ratio; ROP = retinopathy of prematurity; SGA = small for gestational age.
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PCA upon onset of pre-threshold ROP was 35.9±2.7 weeks
forAGAand38.3±1.6weeks forSGApatients.MeanPCAupon
treatment was 37.4±2.7 weeks for AGA patients and
39.9±1.2 weeks for SGA ones. In our cohort, all diagnoses of
indications for ROP treatmentwere found after the initial oph-
thalmologic examination, as per Brazilian guidelines.
Pre-threshold and threshold ROP diagnoses were made, on
average, after 9.1±2.1weeks of life for AGApatients andafter
8.3±1.5 weeks for SGA patients, respectively.
All of our patients were treated at threshold ROP. At the
end of 2003, after our data collection process began, the first
results of ET-ROP were published, suggesting ROP treatment
at pre-threshold ROP. ET-ROP results showed significant
improvements in functional and anatomical outcomes
(decrease from19.5 to 14.5% in loss of visual acuity and from
15.6 to 9.1% in residual retinal damage after nine months)
for patients treatedat pre-thresholdROPwhencomparedwith
patients treatedat thresholdROP.17Wechose tokeep the clas-
sic indication for treatment upon onset of threshold ROP dur-
ing our study, since, in 2003, ET-ROP results were still
considered preliminary, with only nine months of follow-up.
There aremany studieswhich analyze risk factors for ROP.
LowGA, lowBW,maternal essential hypertensionbeforepreg-
nancy,6,26,27 presence of bronchopulmonary dysplasia,6 sep-
sis, and need for oxygen therapy in mechanical ventilation
have been the factors most often related to the onset of ROP.
In a controlled clinical study, Patz et al.28 clearly showed the
cause and effect relation between oxygen therapy and the
onset of ROP. Hypoxia and hyperoxia, as well as fluctuations
in oxygen blood pressure, have been implicated as etiological
factors for ROP. In our study, the use of oxygen therapy in
mechanical ventilation was considered a risk factor for ROP
among AGA patients, but the same was not found for SGA
ones. At our institution, control over oxygen therapy follows
very strict parameters. Pretermpatients arepermanently con-
trolled via pulse oxymetry with saturation pressure stan-
dards between 88 and 94%. The nursing staff is periodically
trained on the relationship between efficient oxygen control
and onset of ROP, and on the need of avoiding fluctuation to
prevent the onset of severe ROP in many cases with these
simples procedures.
Some believe that the onset of ROP takes place among
preterm patients with more comorbidities, but SGA patients
are not always sicker than AGA ones, they only have lower
BW for their respective GA. Being SGA, therefore, can corre-
spond to an anthropometric measure which does not neces-
sarily haveadverse implications for studying theoverall health
of a preterm infant.29 For patients in our study,medianGA for
SGA patients was two weeks higher than the median for AGA
ones (31 vs. 29weeks, respectively). Among the 14 variables
considered as potential risk factors for ROP in the study, six
were significant among AGA patients, while only four of the
sameset of variableswere at all significant for theSGAGroup.
SGA patients showed no statistical significance for ROP
regarding the use of oxygen therapy or to the need for use of
indomethacin (significant variables among AGA patients),
which allowsus to conclude that, eventually, thepatientswere
less sick than patients from the AGA group in our study (Table
2).Wehave also found that AGApatients had lessweight gain
after birth to sixth week of life than SGA ones (556.1±277.2
gramsversus625.6±219.1grams, respectively; that factmay
also be an indication that AGApatients in our study presented
more comorbidities during their stay in theNICU.On theother
hand, some studies show that preterm SGA patients have
higher mortality rates, and higher probability of developing
bronchopulmonary dysplasia and other comorbidities, such
as ROP, and need longer hospital stays.30
Current knowledge about ROP considers it a multifacto-
rial disease. In our study, the main risk factors associated to
the onset of ROP, after univariate analysis, were: low GA, low
BW, low weight gain after birth to sixth week of life, and need
of blood transfusions, for bothpatient groups (AGA/SGA), and
use of indomethacin and need for use of oxygen therapy with
mechanical ventilation only for AGA patients. After adjusted
logistic regression, only low weight gain after birth to sixth
week of life and need for blood transfusions were significant
for onset of ROP among our patients (Table 3).
Being pretermSGA as a risk factor for ROP, as it is in other
studies,7,8,30 was not confirmed by our prospective study;
despite including a significant number of patients (345), there
were no statistically significant differences between patients
born AGA or SGA and the onset of ROP at any stage or severe
ROP which requires treatment. Due to the 40% test power of
our study, our current hypothesis is that being SGA may not
be a risk factor for ROP. In the future, with a larger number of
patients, theremay comenewcontributions to this study from
the attainment of ROP prevalence data adjusted for the vari-
ous GA of the patients. Recently, Dhaliwal et al.31 analyzed
the prevalence of ROP among 1,084 AGA patients and 329
SGA ones, in a cohort from three different secondary and ter-
tiaryhospitals, observed from1990 to2004. Theauthors,who
included patients with BW≤1,500 grams and GA≤ 32weeks
in their study, showed that SGA patients had higher probabil-
ity of developing ROP at any stage, as well as more severe
forms of the disease. The cohort described by Dhaliwal et al.
points at infants smaller than thoseobservedamongourHCPA
patients, because their median BW and GA were 890 grams
and27weeks for AGAand1,035 grams and31weeks for SGA
ones, while our study had medians of 1,170 grams and 29
weeks for AGA patients and 1,112.5 grams and 31 weeks for
SGA ones.
Other studieswhich also sought to analyze the risk of ROP
among SGA patients and found positive results on that front
have made findings in patient groups with different popula-
tion features than those from our group, such as: retrospec-
tive studies which focus on studying patients with 24-26
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weeks of GA8; or studies based on greater restrictions on
growth (<25thpercentile forGA) 32; or different patient inclu-
sion criteria or different percentiles for GA (< 9th percentile
for GA) when defining the SGA group.12
Among other possible limitations of our study, we should
stress that our observations are based on data from a single
NICU, at a single tertiary referral hospital which excels in peri-
natal care.Weshouldalso stress that prospective clinical stud-
ies show findings related to a specific population. Its results
and conclusions should not be extrapolated for patients born
at units with different characteristics or different possibilities
in terms of perinatal care practiced at such institutions.
Our data highlight the importance of neonatal screening
for ROP detection, as well as that the criteria defined for Bra-
zil15 have been effective in finding all 24 threshold cases from
the cohort. The only unfavorable outcome (ROP 5)was due to
loss of patient in follow-up after hospital discharge, with the
patient not showingup for scheduled treatment (Table2). ROP
prevalence in the study is comparable to studies from indus-
trialized countries.33,34
The implementation of screening programs for early
detection and treatment of ROP in other Brazilian hospitals,
as well as better training in ophthalmologic services for prop-
erly following up these young patients, would greatly contrib-
ute to lowering the primary cause of avoidable childhood
blindness in Brazil.
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